Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Johnson & Johnson Files for Arbitration Over Schering Deal

By Pharmaceutical Processing | May 28, 2009

NEW BRUNSWICK, N.J. (AP) — Johnson & Johnson has filed a demand for arbitration to terminate an agreement between its Centocor Ortho Biotech unit and Schering-Plough Corp., in light of the latter company’s impending merger with rival drugmaker Merck & Co. The agreement covers Remicade, a treatment for rheumatoid arthritis and Crohn’s disease, and Simponi, a treatment for rheumatoid arthritis and active psoriatic arthritis. Terminating the deal would return full rights to Johnson & Johnson to distribute these products in markets outside the United States, where Schering-Plough currently has the rights to distribute the drugs. “As its public statements have made clear, Merck is acquiring Schering-Plough,” J&J said late Wednesday. “The acquisition constitutes a change of control that triggers the right of our Centocor Ortho Biotech subsidiary to terminate the agreements.” Whitehouse Station, N.J.-based Merck and Kenilworth, N.J.-based Schering-Plough said they are “fully prepared to arbitrate the matter and to vigorously defend their rights.” Schering-Plough reported in April that its first-quarter Remicade sales rose 2 percent to $518 million. The companies said they are confident an arbitrator will agree that the Merck/Schering-Plough merger does not give Johnson & Johnson the right to terminate the agreement. Their acquisition agreement is structured as a reverse merger, with Schering-Plough as the surviving company, to avoid triggering change-in-control terms in Schering’s deal with Johnson & Johnson. The arbitration process is expected to take place over the next nine to 12 months and could be ongoing after the closing of the companies’ merger, expected in the fourth quarter.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE